Holen Sie sich die Stockscreener-App
128.12
0.13%
0.17
Vorhandelsmarkt:
125.01
-3.11
-2.43%
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx Biosciences urges sustained research to accelerate oncology breakthroughs - Traders Union
Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price Today & Analysis - Gotrade
Inhibrx Biosciences (NASDAQ:INBX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum - Yahoo Finance
INBX Price Today: Inhibrx Biosciences, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Large drugmakers eye Inhibrx cancer drugs valued over $8 billion, stock surges - MSN
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00 - MSN
Inhibrx gains as Stifel issues new buy based on lead assets - MSN
Inhibrx Biosciences president granted 50K options | INBX Insider Trading - Stock Titan
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans - Yahoo Finance
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $200 - Moomoo
Understanding Momentum Shifts in (INBX) - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Upgraded at Lifesci Capital - MarketBeat
This Inhibrx Biosciences analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Inhibrx Biosciences commits to sustainability with new Earth Day measures - Traders Union
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
LifeSci Capital Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $200 - Moomoo
[ARS] Inhibrx Biosciences, Inc. SEC Filing - Stock Titan
Executive pay and board elections detailed in Inhibrx (INBX) 2026 proxy filing - Stock Titan
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges - Sahm
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 9.4%Should You Buy? - MarketBeat
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study - The Globe and Mail
INBX (Inhibrx Biosciences Inc.) reports narrow Q4 2025 EPS beat, shares rise 6.16 percent on upbeat investor sentiment.Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Inhibrx: Spinoff Rumors Send Shares SoaringStunning Bull Run Can Continue (NASDAQ:INBX) - Seeking Alpha
INBX Stock Spikes As Ozekibart Data Fuel Bullish Targets - timothysykes.com
INBX Stock Jumps As Ozekibart Data Draws $150 Target - StocksToTrade
Exclusive: Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
INBX Soars As Ozekibart Data And $150 Target Fire Up Traders - timothysykes.com
Stifel raises Inhibrx Biosciences price target on trial optimism By Investing.com - Investing.com Canada
INBX Stock Jumps As Ozekibart Data And $150 Target Fuel Buzz - StocksToTrade
Inhibrx Biosciences stock surges on takeover interest report By Investing.com - Investing.com Canada
Inhibrx Biosciences (NASDAQ:INBX) Sets New 52-Week HighHere's What Happened - MarketBeat
INBX Stock Whipsaws Higher As Ozekibart Data Fuels Bullish Targets - timothysykes.com
Inhibrx Biosciences stock reaches all-time high of 147.85 USD By Investing.com - Investing.com Australia
INBX jumps after ozekibart colorectal cancer update and regulatory progress - Quiver Quantitative
Inhibrx Biosciences stock reaches all-time high of 147.85 USD - Investing.com
Inhibrx Biosciences Inc. posts narrow EPS beat no quarterly revenue disclosed - UBND thành phố Hải Phòng
Morning Market Movers: AGPU, INBX, HCAI, FLWS See Big Swings - RTTNews
Inhibrx cancer drug reportedly drawing interest of Merck and rivals - Seeking Alpha
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - BioSpace
INBX: Ozekibart plus FOLFIRI delivers durable efficacy and safety in late-line colorectal cancer - TradingView
INBX: Ozekibart plus FOLFIRI showed strong efficacy and safety in late-line CRC, supporting further trials - TradingView
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data - TipRanks
Inhibrx Provides Interim CRC Data: 20% ORR, 5.5M Median PFS; FDA BLA Submitted for Chondrosarcoma - TradingView
87% disease control lifts Inhibrx drug in late-line colorectal cancer - Stock Titan
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):